Results 11 to 20 of about 12,483,860 (378)

Tumor-Associated Antigens in Breast Cancer [PDF]

open access: yesBreast Care, 2012
The targets for the immune system are antigens present on cancer cells; however, many are not cancer-specific and may also be found on normal tissues. These antigens are often products of mutated cellular genes, aberrantly expressed normal genes, or genes encoding viral proteins.
C. Criscitiello
semanticscholar   +5 more sources

Analysis of thymic generation of shared T‐cell receptor α repertoire associated with recognition of tumor antigens shows no preference for neoantigens over wild‐type antigens [PDF]

open access: yesCancer Medicine, 2023
Background The number of mutations in cancer cells is an important predictor of a positive response to cancer immunotherapy. It has been suggested that the neoantigens produced by these mutations are more immunogenic than nonmutated tumor antigens, which
Joonatan Mattila   +5 more
doaj   +2 more sources

BamQuery: a proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens [PDF]

open access: yesGenome Biology, 2023
MHC-I-associated peptides deriving from non-coding genomic regions and mutations can generate tumor-specific antigens, including neoantigens.
Maria Virginia Ruiz Cuevas   +12 more
doaj   +3 more sources

Engineered human B cells targeting tumor-associated antigens exhibit antigen presentation and antibody-mediated functions [PDF]

open access: yesFrontiers in Immunology
B cell engineering represents a promising therapeutic strategy that recapitulates adaptive immune functions, such as memory retention, antibody secretion and affinity maturation in murine models of viral infection.
Alexander Boucher   +26 more
doaj   +2 more sources

Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer

open access: yesTumor Biology, 2017
We evaluated autoantibodies against nine tumor-associated antigens, including p62, p16, Koc, p53, Cyclin B1, Cyclin E, Survivin, HCC1, and RalA as serological markers in lung cancer.
Pei Li   +5 more
doaj   +2 more sources

Screening of novel tumor-associated antigens for lung adenocarcinoma mRNA vaccine development based on pyroptosis phenotype genes [PDF]

open access: yesBMC Cancer
This study aimed to identify new pyroptosis-associated tumor antigens for use in mRNA vaccines and the screening of sensitive LUAD populations suitable for vaccination.
Fang Zhou   +4 more
doaj   +2 more sources

SARS-CoV-2-specific T cells cross-react with tumor-associated antigens via molecular mimicry. [PDF]

open access: goldJ Transl Med
Ragone C   +7 more
europepmc   +3 more sources

Autoantibody to GNAS in Early Detection of Hepatocellular Carcinoma: A Large-Scale Sample Study Combined with Verification in Serial Sera from HCC Patients

open access: yesBiomedicines, 2022
The aim of this study was to explore the value of autoantibody to GNAS in the early detection of hepatocellular carcinoma (HCC). In a large-scale sample set of 912 participants (228 cases in each of HCC, liver cirrhosis (LC), chronic hepatitis B (CHB ...
Xiao Wang   +7 more
doaj   +1 more source

Cancer Vaccines: Antigen Selection Strategy

open access: yesVaccines, 2021
Unlike traditional cancer therapies, cancer vaccines (CVs) harness a high specificity of the host’s immunity to kill tumor cells. CVs can train and bolster the patient’s immune system to recognize and eliminate malignant cells by enhancing immune cells ...
Yue Zhao   +5 more
doaj   +1 more source

Development of a multi-epitope mRNA vaccine targeting tumor-associated antigens for esophageal squamous cell carcinoma. [PDF]

open access: goldNPJ Vaccines
Zhang H   +18 more
europepmc   +3 more sources

Home - About - Disclaimer - Privacy